Breast Cancer

Dr Kettle provide insights into unmet needs surrounding treatment of metastatic breast cancer.

Drs DiMarco and Moore weigh the benefits and barriers associated with clinical pathways in treating patients with mBC.

Medical experts weigh in on key points of emphasis surrounding medication therapy management for patients diagnosed with mBC

Researchers determined that simultaneously targeting the BRD4 and LOXL2 proteins disrupts their interaction and inhibits the growth of triple-negative breast cancer cells.

Dr Kettle outlines NCCN guideline-directed therapy surrounding CDK4/6 inhibitors.

Adverse event profiles of several approved CDK4/6 inhibitors are discussed.

Compared to endocrine therapy alone, the combination of ribociclib and endocrine therapy lowered the risk of cancer recurrence in patients with early breast cancer by 25.2%.

Jacob Kettle, PharmD, BCOP, joins Drs Haumschild and DiMarco in a conversation surrounding findings from the SONIA trial and their impact on shifting mBC treatment strategies.

Expert panelists discuss the impact of CDK4/6 inhibitor therapy on progression-free and overall survival.

This finding underlines the need for methods that address multiple genomic alterations and targeted therapies effective in tumors driven by variations in suppressor genes or transcription factors.

Mental health treatment may be necessary when SAEs occur.

Dr Moore examines findings from the NATALEE trial.

The pharmacist’s role in addressing treatment failure for patients receiving CDK4/6 inhibitors is examined.

Rose DiMarco, PharmD, BCPS, BCOP, addresses strategies to maximize patient adherence to CDK4/6 inhibitor therapy.

Larger institutions have continued to treat patients who needed carboplatin or cisplatin; however, the survey results don’t include smaller cancer centers that may face access challenges.

Not only did the Navya-Patient Preference Tool help patients with decision-making, but groups who used the tool were more likely to receive their preferred form of surgery.

The manager of patient support services at St. Luke’s Cancer Center discusses the significance of Reaching Out for Healthy Women and how female patients can receive support from this initiative.

Lack of awareness, cultural beliefs, and physician preferences may influence whether minority patients receive palliative care during metastatic breast cancer treatment.

Ongoing studies utilizing large-scale health databases that incorporate environmental, lifestyle, biological, and phenotypic data may provide insight that leads to better cancer prevention and treatment.

Ryan Haumschild, PharmD, MS, MBA, leads drives a conversation surrounding the impact of CDK4/6 inhibitors in treatment of metastatic breast cancer.

A panel of medical experts begin a discussion surrounding key updates in treatment and management of HR+/HER2- metastatic breast cancer.

The study authors suggest that after initiating alpelisib, patients should be proactive by improving glycemic status to reduce the risk of developing hyperglycemia.

Dr Moore provides a detailed summary of the scope and findings from the TROPiCS-02 study.

Heather Moore, CPP, PharmD, highlights key contributions from pharmacists in breast cancer treatment and identifies current unmet needs in the treatment landscape.

Investigators found an approximately 23% decrease in overall cancer incidence in April 2020, specifically for breast, colon, rectal, head and neck cancers, as well as melanoma and endocrine cancer diagnoses.

AACR has urged Congress to provide billions more in funding for cancer research, prevention efforts, and expedited review of cancer-related medical products.

Researchers found an increased risk of breast cancer in women who had higher particulate matter levels near their home.

The CDK12/13 inhibitor will be tested for efficacy and safety in patients with advanced solid tumors, such as breast, ovarian, and Ewing Sarcoma.

Precision medicine in pharmacy has the potential to revolutionize patient care by optimizing drug selection, dosing, and monitoring.